Company Overview
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
Recent Developments
- Apr 2026 Revenue of $4.32K (-0.7% YoY); net profit $-9.14M.
- Trailing 12 Months Year-on-year growth — revenue +10.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -26.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -25.96% |
| 1 Year: | 10.50% |
Stock Price Performance
| 1 Year: | +16.24% |
| 6 Months: | +53.61% |
| 3 Months: | +121.74% |
| 1 Month: | +101.98% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross5d ago
- RSI (14)79.43 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -26.0% CAGR over 5 years.
- RSI at 79 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HSCS HeartSciences Inc. PHARMA | 4.08 | -1.48 | $19.58M | 0.00% | - | - | -25.96% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jul 2021 | Oct 2021 | Jan 2022 | Jul 2022 | Oct 2022 | Jan 2023 | Jul 2023 | Oct 2023 | Jan 2024 | Jul 2024 | Oct 2024 | Jan 2025 | Jul 2025 | Oct 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.48K | - | 2.74K | 3.20K | - | 1.95K | - | 3.90K | 14.70K | - | - | 0 | 1.90K | 2.42K | 0 |
| Gross Profit | 1.73K | - | 1.89K | 1.16K | - | 1.19K | - | 2.38K | 10.14K | - | - | 0 | 1.14K | 1.41K | 0 |
| Operating Income | -674.45K | -956.86K | -1.10M | -1.43M | -1.77M | -1.31M | -1.33M | -1.57M | -1.53M | -2.08M | -1.99M | -2.37M | -1.87M | -2.07M | -1.93M |
| Net Income | -501.85K | -1.03M | -1.24M | -1.57M | -1.81M | -1.34M | -1.37M | -1.75M | -1.64M | -2.05M | -2.08M | -2.54M | -2.05M | -2.35M | -1.99M |
| Diluted EPS | -0.15 | -0.31 | -0.37 | -0.28 | -0.22 | -0.16 | -13.23 | -15.92 | -3.01 | -2.64 | -2.27 | -2.57 | -1.58 | -0.85 | - |
| R&D Expense | 401.11K | 545.77K | 699.01K | 434.20K | 848.98K | 643.26K | 565.63K | 757.30K | 509.51K | 1.22M | 1.20M | 1.03M | 997.21K | 727.03K | 638.58K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|
| Revenue | 14.37K | 5.15K | 18.60K | 4.35K | 4.32K |
| Gross Profit | 6.48K | 2.35K | 12.52K | 2.47K | 2.55K |
| Operating Income | -4.71M | -6.11M | -6.31M | -8.35M | -8.41M |
| Net Income | -4.83M | -6.35M | -6.61M | -8.77M | -9.14M |
| Diluted EPS | -1.45 | -80.00 | -18.74 | -9.34 | - |
| R&D Expense | 3.00M | 2.46M | 2.88M | 4.39M | 2.84M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Dec 2025 | Apr 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.09M | 3.29M | 9.50M | 4.22M | 4.22M | - | 5.26M |
| Total Equity | -1.91M | -6.06M | 230.56K | 7.32M | 205.17K | 205.17K | 226.06K | 226.06K |
| Cash & Equivalents | - | 918.26K | 1.66M | 5.81M | 1.10M | 1.10M | 1.70M | 1.66M |
| Total Liabilities | - | 8.15M | 3.06M | 2.19M | 4.02M | 4.02M | - | 5.04M |
| Current Liabilities | - | 3.47M | 1.83M | 1.75M | 3.70M | 3.70M | - | 4.86M |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | -3.64M | -5.77M | -6.07M | -7.41M | -7.43M |
| Investing Cash Flow | -1.93K | -18.31K | -125.27K | -30.19K | -44.45K |
| Financing Cash Flow | 3.84M | 6.53M | 10.34M | 2.73M | 8.03M |
| Capital Expenditure | -1.93K | -18.31K | -64.45K | -3.16K | -3.55K |
| Free Cash Flow | -3.65M | -5.79M | -6.13M | -7.42M | -7.43M |
Ratios (Annual)
Figures in %.
| Metric | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|
| Gross Margin % | 45.1% | 45.7% | 67.3% | 56.8% | 59.1% |
| Operating Margin % | -32,765.6% | -118,698.3% | -33,902.0% | -192,013.1% | -194,787.4% |
| Net Margin % | -33,592.6% | -123,384.3% | -35,511.9% | -201,499.5% | -211,666.5% |
| ROE % | 79.7% | -2,756.1% | -90.3% | -4,272.2% | -4,044.0% |
| ROCE % | 341.0% | -420.3% | -81.4% | -1,607.2% | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | TFB Advisors LLC | 0.62% | 29.74K | $154.65K |
| 2 | Geode Capital Management, LLC | 0.48% | 23.05K | $119.85K |
| 3 | Astoria Strategic Wealth, Inc. | 0.39% | 18.93K | $98.42K |
| 4 | Vanguard Capital Management LLC | 0.37% | 17.97K | $93.43K |
| 5 | Vanguard Fiduciary Trust Co | 0.36% | 17.24K | $89.64K |
| 6 | Tradition Wealth Management, LLC | 0.35% | 16.82K | $87.46K |
| 7 | Citadel Advisors Llc | 0.30% | 14.49K | $75.34K |
| 8 | Citigroup Inc. | 0.12% | 5.86K | $30.47K |
| 9 | UBS Group AG | 0.12% | 5.81K | $30.22K |
| 10 | Tower Research Capital LLC (TRC) | 0.03% | 1.57K | $8.15K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HSCS
HSCS - HeartSciences Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBNSzNteFY5clZjTEhNb0VQR3VQNTh2dUZ0RzNiejJtMXBXRHRERWpkNl9xVS1HQTY5S1VWMmMxUWxhTjRZSEE?oc=5" target="_blank">HSCS - HeartSciences Inc Stock Price and Quote</a> <font colo…
DCG stake sets up voting control of HeartSciences (HSCS) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNNldJOWdlUDlmOHFZd0xsMkV6QWJYZTNlb2xVVUtxeS1mRlNldXgwbVptUUZJRHE4dWV6bXVpSHhLTUNicmpNMGpLc0tTZWR1VDNUM2FMeXNJWHhCY3ljeVRhQ2ZSeUM0OWVENjNLck5hNGt0Q1VLS2ZYa2tRTnlrSmwzMnpfTTFOa1RDSF…
Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets - Business Wire
<a href="https://news.google.com/rss/articles/CBMivwJBVV95cUxQRF9MQkhnMkcwZUJKb2s3Q1JZeDk1NE5KTHJ3aXpnVlJTb2VYY2RIdUd5Nkc0aHBxUXVuVXpENmpOVjBRRW5vOV95TDY0MmdJR1d3WGF5WDdwY183LUhDZkVqc1lPYjg0U1VwazZaV2diMklOamloSTJKbExqbVdPaTZWSDZRckhNQzR4Z2…
HeartSciences Surges on Planned Merger With Zcash Mining Platform Fortitude | HSCS Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNMllSX3M4NG8xVGl5Q3dBalBsbDdjWEdrcXZzOXdjWlpkdk9Sa2k1WVp4bzc4U0NfQWxLajFIUGswMGdxcmtCZXlsdFYxV0FPMkk0eXpRYUd1a1pTNHF3VnZEZ2FxMUZpMU85SVZGVWphZkhDT0o0WUhwamQzUWZRb1czYW5rZ0tvYjlPej…
HSCS Stock Pops As European Patent Expands AI Heart Tech - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5NYzBYZkVYb0toeXZ1dWxrbnpWVVQ5RXRNS241RnVVaXRHcl9zSWhHSlJmWUFocWhNaEVoVk5QcXljZUlvYVB6YS1QTndBUm5lYzE1M0RrR05PU3ZScm1aS3B5VFpRdXZYX2V5NWh3aFIyTW5ESVJWRHBn?oc=5" target="_blank">HSC…
Should I buy HeartSciences Inc. (HSCS) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTFBuTjdVenVLY29XVW1FS2ZmeXNGUEkxSWcxWm5feWhIdVpha2dkSlV3X3lROUZMOWpCQW1wOVZuVVlLamNIMno4U05tejE2M3pNWC1EcURuQWNzZ21FLXpLLWVWbGdvMVhsNTNqNw?oc=5" target="_blank">Should I buy HeartSci…
HSCS — Frequently Asked Questions
What is the current share price of HeartSciences Inc. (HSCS)?
As of 2026-09-19 21:16 PDT, HeartSciences Inc. (HSCS) trades at $4.08 on NasdaqCM. Its 52-week range is $1.67 to $4.08.
What is the market capitalisation of HSCS?
HeartSciences Inc. (HSCS) has a market capitalisation of $19.58M on NasdaqCM.
What is the P/E ratio of HSCS?
HSCS trades at a trailing price-to-earnings (P/E) ratio of -1.48. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 73.24.
Is HSCS a good stock to buy?
This page provides a data-driven analysis of HeartSciences Inc. (HSCS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.